Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$8.77 USD
+0.45 (5.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.76 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Vir Biotechnology, Inc. [VIR]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Hepatitis Delta Combination Therapy Reveals Best-in-Class Potential in Interim Phase 2 Data Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
BioConnect Conference Takeaways: Bright Spotlight on Viral Hepatitis Programs Ahead of Next Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Key Near-Term Phase 2 Readouts With Potential Best-in-Class Regimens in HDV and HBV On-Track; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaway From Biotech Breakthroughs HBV Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Potential Best-in-Class Regimens in Viral Hepatitis B and D Poised to Shine in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Positioned For Leadership in the Coming Hepatitis B Breakthrough Boom; Upping Price Target to $110; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
HDV and HBV Programs on Track For Key Phase 2 Readouts in 2024 and 2025; Modulating Price Target to $85; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Announces Cost Optimization to Drive $40M Annual Savings; HBV Program on Track for Phase 2 Readouts in 2024; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for VIR 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Vaccinal Effect Could Explain the Unprecedented Functional Cure Rates at 24 Weeks; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
HBV Program on Track For Potentially Unprecedented Functional Cure Rates; HDV Program Impresses; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Nearing Phase 2 Data Readouts in HBV and HDV
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
HBV Conference Takeaways: Expect Compelling Phase 2 Combination Regimen Data at AASLD in November
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Bright Spotlight on Phase 2 Data in Chronic HBV Program in 4Q23; Lowering PT to $95 on Flu False Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
PENINSULA Disappoints; Next Gen Flu Program Emerges; Spotlight Shifts to HBV Program Updates Expected in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Evidence Building in Favor of VIR-2218 Plus VIR-3434 Combination as Functional Cure For Chronic HBV
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Pipeline Progressing; Crucial Near- Term HBV and Influenza Phase 2 Data Readouts on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; HBV, Flu, and HIV Programs Take Center Stage as COVID-19 Exits; Lowering Price Target to $100; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department